"Although the revenue has been flat year-over-year, the marginal decline in profit was primarily due to write-off of Oseltamivir inventory by our marketing partner in the USA. The flu season in USA was weaker than expected, resulting in the write-off of inventory valued at approximately $5.5 million. On the domestic front, in spite of intense price pressures, the company has seen growth in the oncology segment," Natco Pharma
Formulations exports accounted for 39.78 per cent of the total revenues in FY19, while the share of domestic formulations business was 33 per cent.
The board of directors of the company declared a third interim dividend of Rs 1.25 per equity share of Rs 2 apiece, resulting in a total dividend payout of Rs 6.25 per equity share for FY19.